


1657  
RECEIVED

JAN 14 2002

TECH CENTER 1600/2900

PATENT APPLICATION  
Attorney Docket No.: BURF-P01-006

DYH:kfd  
October 22, 2001



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Fallon, et al.  
Application No.: 09/715,836      Group Art Unit: 1651  
Filed: November 17, 2000      Examiner: N/A  
For: BIGLYCAN AND RELATED THERAPEUTICS AND  
METHODS OF USE

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as  
First Class Mail, postage prepaid, in an envelope addressed to: Assistant Commissioner for Patents,  
United States Patent and Trademark Office, Washington, D.C. 20231.

October 22, 2001  
Date

Karen DiRocco  
Karen DiRocco

TRANSMITTAL OF SEQUENCE LISTING IN RESPONSE TO NOTICE TO  
COMPLY WITH 37 C.F.R. §§1.821-1.825

Box Sequence  
Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

This amendment is submitted in response to the Notice to Comply with  
Requirements for Patent Applications Containing Nucleotide Sequence and/or  
Amino Acid Sequence Disclosures attached thereto, mailed from the Patent Office  
on October 2, 2001, copies of which are attached.

Transmitted herewith is a copy of the "Sequence Listing" in paper form for the above-  
identified patent application as required by 37 C.F.R. §1.821(c) and a copy of the "Sequence

Listing" in computer readable form as required by 37 C.F.R. §1.821(e). As required by 37 C.F.R. §1.821(f), Applicant's Attorney hereby states that the content of the "Sequence Listing" in paper form and the computer readable form of the "Sequence Listing" are the same and, as required by 37 C.F.R. §1.821(g), also states that the submission includes no new matter.

Respectfully submitted,

ROPES & GRAY



---

David P. Halstead

Registration No. 44,735

Telephone (617) 951-7000

Facsimile (617) 951-7050

Boston, Massachusetts 02110

Date: October 22, 2001